Venmax Drugs and Pharmaceuticals Limited (BOM:531015)
12.36
-2.66 (-17.71%)
At close: Nov 16, 2026
BOM:531015 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 132.58 | 80.25 | 8.07 | - | - | - | |
Revenue Growth | 333.17% | 894.04% | 380.89% | - | - | - |
Cost of Revenue | 122.52 | 72.84 | 7.95 | 0.1 | - | - |
Gross Profit | 10.06 | 7.41 | 0.12 | -0.1 | - | - |
Selling, General & Admin | 2.13 | 2.1 | 0.66 | 0.23 | 0.3 | 0.19 |
Other Operating Expenses | 4.16 | 3.87 | -0.65 | 0.73 | 1.55 | 1.08 |
Operating Expenses | 6.33 | 6 | 0.08 | 1.02 | 1.94 | 1.36 |
Operating Income | 3.73 | 1.4 | 0.05 | -1.12 | -1.94 | -1.36 |
Interest & Investment Income | 1.37 | 1.37 | - | - | - | - |
Other Non Operating Income (Expenses) | - | 0 | -0 | 1.99 | 4.19 | 19.83 |
EBT Excluding Unusual Items | 5.11 | 2.77 | 0.05 | 0.87 | 2.26 | 18.47 |
Asset Writedown | - | - | -0.19 | - | - | - |
Pretax Income | 5.11 | 2.77 | -0.14 | 0.87 | 2.26 | 18.47 |
Income Tax Expense | 0.87 | 0.29 | -0.04 | 0.22 | 0 | 0 |
Net Income | 4.23 | 2.48 | -0.11 | 0.65 | 2.26 | 18.46 |
Net Income to Common | 4.23 | 2.48 | -0.11 | 0.65 | 2.26 | 18.46 |
Net Income Growth | 22.73% | - | - | -71.41% | -87.78% | - |
Shares Outstanding (Basic) | 16 | 12 | 5 | 5 | 5 | 5 |
Shares Outstanding (Diluted) | 16 | 12 | 5 | 5 | 5 | 5 |
Shares Change | 216.05% | 121.09% | - | - | - | 0.00% |
EPS (Basic) | 0.26 | 0.21 | -0.02 | 0.12 | 0.43 | 3.52 |
EPS (Diluted) | 0.25 | 0.21 | -0.02 | 0.12 | 0.43 | 3.52 |
EPS Growth | -61.62% | - | - | -72.09% | -87.78% | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -116.92 | -109.96 | -22.9 | 0.02 | -0.03 | 19.05 |
Free Cash Flow Per Share | -7.12 | -9.49 | -4.37 | 0.00 | -0.01 | 3.64 |
Gross Margin | 7.59% | 9.23% | 1.52% | - | - | - |
Operating Margin | 2.81% | 1.75% | 0.58% | - | - | - |
Profit Margin | 3.19% | 3.09% | -1.30% | - | - | - |
Free Cash Flow Margin | -88.19% | -137.03% | -283.69% | - | - | - |
EBITDA | 3.78 | 1.44 | 0.11 | -1.05 | -1.86 | -1.27 |
EBITDA Margin | 2.85% | 1.80% | 1.38% | - | - | - |
D&A For EBITDA | 0.05 | 0.04 | 0.06 | 0.07 | 0.08 | 0.09 |
EBIT | 3.73 | 1.4 | 0.05 | -1.12 | -1.94 | -1.36 |
EBIT Margin | 2.81% | 1.75% | 0.58% | - | - | - |
Effective Tax Rate | 17.10% | 10.37% | - | 25.74% | 0.04% | 0.02% |
Revenue as Reported | 134.18 | 81.85 | 18.61 | 1.99 | 4.19 | 19.83 |
Advertising Expenses | - | 0.07 | 0.07 | - | - | - |